Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 2, 2013, Pages 243-250

  Lamond, Nathan W D ^a   Skedgel, Chris ^b   Younis, Tallal ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

21 gene recurrence score; breast cancer; cost effectiveness; cost utility; gene expression

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN;

21 GENE RECURRENCE SCORE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ENDOCRINE SENSITIVE NODE NEGATIVE BREAST CANCER; GENE EXPRESSION PROFILING; HUMAN; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84876151111     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.4     Document Type: Review

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
2. Broekx S, Den Hond E, Torfs R et al. The costs of breast cancer prior to and following diagnosis. Eur. J. Health Econ. 12(4), 311-317 (2011
3. Burstein HJ, Prestrud AA, Seidenfeld J et al.; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784-3796 (2010
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes- dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736-1747 (2011
5. Carlson RW, Allred DC, Anderson BO et al.; NCCN Breast Cancer Clinical Practice Guidelines Panel. Breast cancer. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 7(2), 122-192 (2009
6. Fisher B, Jeong JH, Bryant J et al.; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364(9437), 858-868 (2004
7. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res. 9(6), R81 (2007
8. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004
9. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002
10. Ma XJ, Wang Z, Ryan PD et al. A twogene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6), 607-616 (2004
11. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320(8), 479-484 (1989
12. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006
13. Fisher B, Dignam J, Wolmark N et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 89(22), 1673-1682 (1997
14. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006
15. Paik S, Shak S, Tang G et al. Risk classification of breast cancer patients by the recurrence score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. Presented at: The 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2004
16. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23(12), 2716-2725 (2005
17. Bryant J. Oncotype Dx correlates more closely with prognosis than Adjuvant Online. Presented at: 9th International Conference on Primary Therapy of Early Breast Cancer. St Gallen, Switzerland, 26-29 January 2005
18. Mamounas EP, Tang G, Fisher B et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J. Clin. Oncol. 28(10), 1677-1683 (2010
19. Chang JC, Makris A, Gutierrez MC et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res. Treat. 108(2), 233-240 (2008
20. Toi M, Iwata H, Yamanaka T et al.; Japan Breast Cancer Research Group-Translational Research Group. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 116(13), 3112-3118 (2010
21. Lo SS, Mumby PB, Norton J et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J. Clin. Oncol. 28(10), 1671-1676 (2010
22. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4), 381-387 (2010
23. Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX®) in estrogen receptor positive (ER+) node negative (pN0) Breast Cancer in Academic Canadian Centers. Presented at: 2012 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2012
24. Gligorov J, Pivot XB, Naman HL et al. Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early stage breast cancer in France. Presented at: 2012 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2012
25. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J. Oncol. Pract. 3(4), 182-186 (2007
26. Asad J, Jacobson AF, Estabrook A et al. Does Oncotype DX recurrence score affect the management of patients with earlystage breast cancer? Am. J. Surg. 196(4), 527-529 (2008
27. Kamal AH, Loprinzi CL, Reynolds C et al. How well do standard prognostic criteria predict Oncotype DX scores? J. Clin. Oncol. 25, Abstract 18S 576 (2007
28. Hassett MJ, Silver SM, Hughes ME et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J. Clin. Oncol. 30(18), 2218-2226 (2012
29. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol. 4(5), 603-610 (2008
30. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptorpositive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313-324 (2005
31. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: An economic analysis based on prognostic and predictive validation studies. Cancer 109(6), 1011-1018 (2007
32. Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptasepolymerase chain reaction assay in lymph-node-negative, estrogen-receptorpositive, early-stage breast cancer in Japan. Breast Cancer Res. Treat. 112(1), 175-187 (2008
33. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 15(5), 457-465 (2010
34. Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res. Treat. 127(3), 739-749 (2011
35. Hornberger J, Chien R, Krebs K, Hochheiser L. US insurance program's experience with a multigene assay for early-stage breast cancer. J. Oncol. Pract. 7(3S), e38-e45 (2012
36. Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in nodenegative and node-positive breast cancer. Breast Cancer Res. Treat. 133(3), 1115-1123 (2012
37. Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 27(10), 953-959 (2009
38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005
39. Snow S, Rayson D, Barnes PJ, Sellon M, Thompson K, Younis T. Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis. Presented at: American Society of Clinical Oncology Breast Cancer Symposium. Washington DC, USA, 5-7 September 2008
40. Albain KS, Barlow WE, Shak S et al.; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55-65 (2010
41. Gonzalez-Angulo AM, Barlow WE, Gralow J et al. SWOG S1007: A Phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. Presented at: 2011 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2012
42. Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J. Natl Cancer Inst. 104(1), 56-66 (2012